Selurampanel

Selurampanel (INN, code name BGG492) is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy.^[1][2][3] It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects.^[4]

Selurampanel

Clinical data
ATC code	None
Identifiers
IUPAC name N-[7-Isopropyl-6-(2-methylpyrazol-3-yl)-2,4-dioxo-1H-quinazolin-3-yl]methanesulfonamide
CAS Number	912574-69-7
PubChem CID	45381907
ChemSpider	32698379
UNII	7WG1MR7DAR
CompTox Dashboard (EPA)	DTXSID00238467
Chemical and physical data
Formula	C16H19N5O4S
Molar mass	377.42 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)c1cc2c(cc1c3ccnn3C)c(=O)n(c(=O)[nH]2)NS(=O)(=O)C
InChI InChI=1S/C16H19N5O4S/c1-9(2)10-8-13-12(7-11(10)14-5-6-17-20(14)3)15(22)21(16(23)18-13)19-26(4,24)25/h5-9,19H,1-4H3,(H,18,23) Key:MCECSFFXUPEPDB-UHFFFAOYSA-N